[go: up one dir, main page]

LV5793B4 - Glutathione derivatives and their use in medicine - Google Patents

Glutathione derivatives and their use in medicine

Info

Publication number
LV5793B4
LV5793B4 LV960291A LV960291A LV5793B4 LV 5793 B4 LV5793 B4 LV 5793B4 LV 960291 A LV960291 A LV 960291A LV 960291 A LV960291 A LV 960291A LV 5793 B4 LV5793 B4 LV 5793B4
Authority
LV
Latvia
Prior art keywords
glutathione
medicine
many disorders
glutathione derivatives
ester
Prior art date
Application number
LV960291A
Other languages
Latvian (lv)
Other versions
LV5793A4 (en
Inventor
Gerhard Ohlenschlaeger
Original Assignee
Gerhard Ohlenschlaeger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gerhard Ohlenschlaeger filed Critical Gerhard Ohlenschlaeger
Publication of LV5793A4 publication Critical patent/LV5793A4/en
Publication of LV5793B4 publication Critical patent/LV5793B4/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)

Abstract

Two glutathione thiol derivatives, namely the monomethyl ester and the monoethyl ester of reduced glutathione, are proposed for use as medicaments for a wide range of different indications, also in combination with vitamins, an amino acid or a substance which contains a semiconductor element in inorganically or organically bound form. The proposal is based on the knowledge that many disorders of cell metabolism can be rectified by glutathione therapy and therefore many disorders which are accompanied or caused by the loss of the reductive potential can be cured.
LV960291A 1987-07-09 1996-07-22 Glutathione derivatives and their use in medicine LV5793B4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19873722647 DE3722647A1 (en) 1987-07-09 1987-07-09 GALENIC USE OF A TRIPEPTID AS A MEDICINAL PRODUCT
EP88905695A EP0327612B1 (en) 1987-07-09 1988-07-08 Pharmaceutical therapeutic use of glutathione derivatives

Publications (2)

Publication Number Publication Date
LV5793A4 LV5793A4 (en) 1997-02-20
LV5793B4 true LV5793B4 (en) 1997-04-20

Family

ID=6331195

Family Applications (1)

Application Number Title Priority Date Filing Date
LV960291A LV5793B4 (en) 1987-07-09 1996-07-22 Glutathione derivatives and their use in medicine

Country Status (8)

Country Link
EP (2) EP0655460B1 (en)
JP (3) JP2851289B2 (en)
AT (2) ATE188968T1 (en)
AU (1) AU1994488A (en)
DE (1) DE3722647A1 (en)
HK (1) HK74697A (en)
LV (1) LV5793B4 (en)
WO (1) WO1989000427A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075010A (en) * 1992-06-09 2000-06-13 Neorx Corporation Small molecular weight ligand-hexose containing clearing agents
JP2815179B2 (en) * 1989-07-14 1998-10-27 千寿製薬株式会社 Anti-inflammatory and / or anti-allergic agent
WO1991002810A1 (en) * 1989-08-09 1991-03-07 The Children's Medical Center Corporation Nmda oxidizing agents for protecting neurons from injury
JP2919867B2 (en) * 1989-09-27 1999-07-19 千寿製薬株式会社 Antitumor agent
JP2919870B2 (en) * 1989-09-29 1999-07-19 千寿製薬株式会社 Liver damage inhibitor
DE69122831T2 (en) * 1990-04-26 1997-03-27 Senju Pharma Co S- (LOW FATTY ACIDS) SUBSTITUTED GLUTATHION DERIVATIVES
UA26442C2 (en) * 1990-08-20 1999-08-30 Герхард Оленшлегер PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH DISORDERS OF MATERIAL VOLUME
FR2683722B1 (en) * 1991-11-14 1995-05-24 Arkopharma Laboratoires MEDICAMENT FOR THE BASIC TREATMENT OF BETA-CAROTENE-BASED ASTHMA.
US5976535A (en) * 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
US5911969A (en) 1992-06-09 1999-06-15 Neorx Corporation Pretargeting protocols for enhanced localization of active agents to target sites
US5624896A (en) * 1992-06-09 1997-04-29 Neorx Corporation Clearing agents useful in pretargeting methods
DE69331319T2 (en) * 1992-06-09 2002-08-08 Neorx Corp., Seattle Biotin-DOTA conjugates and their use in "pretargeting" processes
TW225992B (en) * 1992-07-17 1994-07-01 Senju Pharma Co
US5306724A (en) * 1992-08-17 1994-04-26 Clintec Nutrition Company Method for preventing and treating atherosclerosis
DE4329857C2 (en) 1993-09-03 1995-08-24 Deutsches Krebsforsch Connection to strengthen the immune system and immune reactions
GB2312621B (en) * 1996-05-02 1998-03-11 Pharma Nord Uk Limited Anti-oxidant medicament
US6337320B1 (en) * 1996-10-11 2002-01-08 Thione International, Inc. Reparatives for ultraviolet radiation skin damage
WO1998032435A1 (en) * 1997-01-29 1998-07-30 Braswell, A., Glenn Liquid eye drop composition
RU2120297C1 (en) * 1997-10-31 1998-10-20 Товарищество с ограниченной ответственностью "Дека-Н" Method of normalization of metabolic processes in cell and a preparation for these aims
WO2000050060A1 (en) 1999-02-22 2000-08-31 Gernot Treusch Therapeutically active mixture of substances containing s-acetylglutathione and aciclovir
FR2804126B1 (en) * 2000-01-21 2005-09-30 Patrick Rambaud METHOD AND SYSTEM FOR MANAGING LOTS OF IMMUNO-COMPETENT CELLS FROM HUMAN OR ANIMAL SUBJECTS FOR DELAYED USES
US6902718B2 (en) 2000-10-24 2005-06-07 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers
US6881396B2 (en) 2000-10-24 2005-04-19 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic 6-hydroxy-chromans
WO2002060491A2 (en) * 2000-10-24 2002-08-08 Diatide, Inc. Stabilization of radiopharmaceutical compositions using a hydrophilic thioether or a hydrophilic 6-hydroxy chroman
US6989138B2 (en) 2000-10-24 2006-01-24 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers and hydrophilic 6-hydroxy chromans
DE10210427A1 (en) 2002-03-09 2003-10-09 Hans Konrad Mueller-Hermelink Human monoclonal antibody
CA2491669A1 (en) 2002-07-04 2004-01-15 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
CA2545512A1 (en) 2003-11-12 2005-10-13 Oncomab Gmbh Methods of identifying neoplasm-specific antibodies and uses thereof
EP1531162A1 (en) 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
JP5757674B2 (en) * 2005-11-09 2015-07-29 味の素株式会社 Calcium receptor activator
JP2013035772A (en) * 2011-08-05 2013-02-21 Osaka City Univ Leukocyte activation inhibitor
WO2013109421A1 (en) * 2012-01-05 2013-07-25 Guilford Frederick Timothy Liposomally encapsulated reduced glutathione for management of cancer and disruption of cancer energy cycles
AU2013320871A1 (en) * 2012-09-28 2015-04-09 Kyowa Hakko Bio Co., Ltd. Agent for enhancing immunity containing glutathione
ITMI20131856A1 (en) * 2013-11-08 2015-05-09 Gnosis Spa PROCESS FOR THE PREPARATION OF DIFFERENT CRYSTALLINE FORMS OF S-ACETYL GLUTATHY AND THEIR USE IN PHARMACEUTICAL AND NUTRACEUTICAL FORMULATIONS
DE202013010690U1 (en) 2013-11-27 2014-04-10 Erhard Römer Pharmaceutical and therapeutic uses of G-SH (reduced glutathione), SAG (S-acetyl-glutathione) also in the micronized range of 1 to 200 my and 1 to 200 nm
DE102014002913A1 (en) 2014-03-03 2015-09-03 Conrad Leuthaeuser Preparation of a micronization of S-acetylglutathione of a pharmaceutical therapeutic substance with a pilot grinding of 1 <100 μm (micron)
IT202100031985A1 (en) * 2021-12-21 2023-06-21 Innbiotec Pharma S R L PHARMACEUTICAL COMPOSITION BASED ON GLUTATHIE THIOESTER AND OLEUROPEIN FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STATEATOHEPATITIS
CN116037240B (en) * 2022-11-25 2023-08-01 杭州皓丰生物技术有限公司 A liquid-transfering gun head for suspending quick liquid of cell

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB144404A (en) * 1919-03-21 1920-06-17 Alexander James Ernest Geairns Improvements in fuel and air supplying arrangements for internal combustion engines
US1444024A (en) * 1920-08-31 1923-02-06 John S Burdick Adjustable seat
GB1444024A (en) * 1973-07-20 1976-07-28 Passwaterr A Food and feed supplents
DE2813814A1 (en) * 1978-03-31 1979-10-18 Boehringer Mannheim Gmbh Increasing the enteral reabsorption of pharmaceuticals - by administration together with an aminoacid or a peptide
RO79426B1 (en) * 1982-02-23 1984-07-30 Romulus Constantin Dinu Medicinal composition for treating neuroviroses
JPH0695945B2 (en) * 1986-10-09 1994-11-30 マルハ株式会社 Acetyl CoA manufacturing method

Also Published As

Publication number Publication date
EP0655460A1 (en) 1995-05-31
HK74697A (en) 1997-06-13
WO1989000427A1 (en) 1989-01-26
DE3722647A1 (en) 1989-01-19
EP0327612A1 (en) 1989-08-16
JPH11147836A (en) 1999-06-02
LV5793A4 (en) 1997-02-20
EP0655460B1 (en) 2000-01-19
ATE121942T1 (en) 1995-05-15
HK1014190A1 (en) 1999-09-24
JP2851289B2 (en) 1999-01-27
EP0327612B1 (en) 1995-05-03
JPH11106349A (en) 1999-04-20
JPH02500841A (en) 1990-03-22
ATE188968T1 (en) 2000-02-15
AU1994488A (en) 1989-02-13

Similar Documents

Publication Publication Date Title
LV5793B4 (en) Glutathione derivatives and their use in medicine
DE3682457D1 (en) DEVICE FOR THE ADMINISTRATION OF MEDICINES TO PATIENTS.
GR3018541T3 (en) Condensed heterocyclic compounds and their use in therapy.
DK414389D0 (en) PHARMACEUTICAL PREPARATION CONTAINING AN AMINO ACID DERIVATIVE WITH PURINE-INHIBITORIAL EFFECT
DK0562512T3 (en) Sulfonamidocarbonylpyridine-2-carboxylic acid amides as well as their use as drugs
DE60207951D1 (en) Pharmaceutical formulations of thyroid hormones
DK312781A (en) INTERNAL CONNECTION IN TRAINING SUBJECTS
DK0602686T3 (en) Lectin concentrates of mistletoe extracts and similarly standardized, stabilized mistletoe lectin preparations, processes for their preparation as well as drugs containing them and their use for increasing ...
DK481389D0 (en) CYCLIC COMPOUNDS WITH INHIBITIVE EFFECTS ON ENZYMET THYMIDYLATE SYNTHASE AND PHARMACEUTICAL MEDICINAL CONTAINING SUCH COMPOUNDS
DK561589D0 (en) LIQUID ORAL PHARMACEUTICAL PREPARATION
DE3862017D1 (en) PHARMACEUTICAL PREPARATION FOR TINEA PEDIS TREATMENT.
Beckmann Phenylalanine in affective disorders.
DK730488A (en) SYNERGISTIC COMBINATION OF DECARBOXYLASE INHIBITORS AND L-DOPA PELLETS
ATE106243T1 (en) USE OF ISOXAZOLINONES AS CEREBRO-ACTIVE MEDICATIONS.
DK157007C (en) VITAMIN D3 DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS, AND USING THESE COMPOUNDS FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF NEOPLASTIC DISEASES OR CURRENT DISEASES OF CURE
DE3476736D1 (en) Use of an antihypoxidoticum with cerebral and peripheral effect
IT1213319B (en) PHARMACEUTICAL COMPOSITION WITH CARDIAC AND METABOLIC PROTECTIVE ACTION ON THE MUSCLE ENERGY METABOLISM.
IT1214708B (en) USE OF DIETYLAMINOETHY-DESTRANE (DEAE-D) AS AN ANTIABETIC DRUG (DIABETES TYPE I-II-III) AND REGULATOR OF GLUCID METABOLISM
Kovacs The question of death in logotherapy.
DE3767055D1 (en) GEL MEDICAL FORM CONTAINING N- (2,6-DICHLOR-M-TOLYL) ANTHRANILIC ACID (MECHLOPHENAMIC ACID) FOR USE IN LOCAL THERAPY.
Lezak Neuropsychology by the Numbers.
Trent et al. The effects of hypnotherapeutic restructuring, systematic desensitization, and expectancy control on mathematics anxiety, attitude, and performance in females and males.
Devi et al. Radioresponse of peripheal blood and its modification by MPG (2-mercaptopropionylglycine) in mice. I. Erythrocytes
Borowitz I. Facilitating treatment of hospitalized patients through administrative supervision of psychoanalytic interns: An interview with Michael Beck.
DK222988A (en) PHARMACEUTICAL PREPARATIONS CONTAINING ORNITHIN-DECARBOXYLASE INHIBITORS